{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:51:28Z","timestamp":1790949088555,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.lanepe.2024.100840","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T08:26:01Z","timestamp":1709540761000},"page":"100840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-5268","authenticated-orcid":false,"given":"Ilias","family":"Houda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dickhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4798-8899","authenticated-orcid":false,"given":"Antonin","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Dziadziuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Pompili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Senan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-608X","authenticated-orcid":false,"given":"Idris","family":"Bahce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lanepe.2024.100840_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100840_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanepe.2024.100840_bib3","author":"Netherlands Cancer Registry"},{"issue":"21","key":"10.1016\/j.lanepe.2024.100840_bib4","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100840_bib5","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/JTO.0b013e3181b9ecca","article-title":"Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials","volume":"4","author":"Lim","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9928","key":"10.1016\/j.lanepe.2024.100840_bib6","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.lanepe.2024.100840_bib13","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl_4","key":"10.1016\/j.lanepe.2024.100840_bib14","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.lanepe.2024.100840_bib15","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","article-title":"Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery","volume":"22","author":"Chang","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100840_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100840_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/JTO.0b013e31824a9022","article-title":"Recurrence dynamics for non\u2013small-cell lung cancer: effect of surgery on the development of metastases","volume":"7","author":"Demicheli","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"issue":"18","key":"10.1016\/j.lanepe.2024.100840_bib18","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100840_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.lanepe.2024.100840_bib20","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/1078-0432.CCR-21-3530","article-title":"Health-related quality of life outcomes in patients with resected epidermal growth factor receptor-mutated non-small cell lung cancer who received adjuvant osimertinib in the phase III ADAURA trial","volume":"28","author":"Majem","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lanepe.2024.100840_bib22","doi-asserted-by":"crossref","first-page":"S1295","DOI":"10.1016\/j.annonc.2023.10.051","article-title":"LBA2 ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanepe.2024.100840_bib23","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1200\/EDBK_321483","article-title":"Immunotherapy for advanced non\u2013small cell lung cancer: a decade of progress","volume":"41","author":"Shields","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100840_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bj.2019.09.002","article-title":"Immune checkpoint inhibitors win the 2018 Nobel Prize","volume":"42","author":"Huang","year":"2019","journal-title":"Biomed J"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100840_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-019-0319-9","article-title":"Harnessing cancer immunotherapy during the unexploited immediate perioperative period","volume":"17","author":"Matzner","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"10308","key":"10.1016\/j.lanepe.2024.100840_bib26","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lanepe.2024.100840_bib29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.lanepe.2024.100840_bib30","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.lanepe.2024.100840_bib31","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2022.40.16_suppl.8512","article-title":"EORTC-1416-LCG\/ETOP 8-15 \u2013 PEARLS\/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use","volume":"40","author":"O'Brien","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.lanepe.2024.100840_bib33","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.lanepe.2024.100840_bib34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non\u2013small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.lanepe.2024.100840_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"issue":"6280","key":"10.1016\/j.lanepe.2024.100840_bib36","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.lanepe.2024.100840_bib37","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100840_bib38","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1038\/s41598-020-63796-w","article-title":"Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model","volume":"10","author":"Mart\u00edn-Ruiz","year":"2020","journal-title":"Sci Rep"},{"issue":"21","key":"10.1016\/j.lanepe.2024.100840_bib39","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanepe.2024.100840_bib40","doi-asserted-by":"crossref","first-page":"S973","DOI":"10.1016\/j.annonc.2022.07.1058","article-title":"932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): health-related quality of life (HRQoL) outcomes from CheckMate 816","volume":"33","author":"Felip","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100840_bib41","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S1556-0864(23)00338-6","article-title":"Neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816","volume":"18","author":"Forde","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.lanepe.2024.100840_bib42","doi-asserted-by":"crossref","first-page":"S1298","DOI":"10.1016\/j.annonc.2023.10.053","article-title":"LBA57 Neoadjuvant nivolumab (N)\u00a0+ chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression","volume":"34","author":"Provencio Pulla","year":"2023","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.lanepe.2024.100840_bib45","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"36_suppl","key":"10.1016\/j.lanepe.2024.100840_bib46","article-title":"Perioperative toripalimab\u00a0+ platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III Neotorch study","volume":"41","author":"Wu","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.lanepe.2024.100840_bib47","doi-asserted-by":"crossref","first-page":"S1295","DOI":"10.1016\/j.annonc.2023.10.050","article-title":"LBA1 CheckMate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II\u2013IIIb NSCLC","volume":"34","author":"Cascone","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.lanepe.2024.100840_bib48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10405","key":"10.1016\/j.lanepe.2024.100840_bib51","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lanepe.2024.100840_bib53","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.lanepe.2024.100840_bib54","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djg059","article-title":"Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer","volume":"95","author":"Scagliotti","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100840_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"Arriagada","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100840_bib56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejcts.2004.03.041","article-title":"Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial","volume":"26","author":"Waller","year":"2004","journal-title":"Eur J Cardio Thorac Surg"},{"issue":"9","key":"10.1016\/j.lanepe.2024.100840_bib57","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.lanepe.2024.100840_bib58","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2008.16.4855","article-title":"Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups","volume":"26","author":"Strauss","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100840_bib59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1200\/JCO.2009.24.0333","article-title":"Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10","volume":"28","author":"Butts","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.lanepe.2024.100840_bib60","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.2009.27.6204","article-title":"Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non\u2013small-cell lung cancer","volume":"28","author":"Felip","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.lanepe.2024.100840_bib61","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2010.33.7089","article-title":"Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non\u2013small-cell lung cancer","volume":"30","author":"Scagliotti","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.lanepe.2024.100840_bib62","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/EDBK_242229","article-title":"Patient-centered cancer drug development: clinical trials, regulatory approval, and value assessment","volume":"39","author":"Gyawali","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.lanepe.2024.100840_bib63","doi-asserted-by":"crossref","first-page":"JCO2300258","DOI":"10.1200\/JCO.23.00258","article-title":"Early-stage lung cancer: using circulating tumor DNA to get personal","volume":"41","author":"Bestvina","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.lanepe.2024.100840_bib64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2023.01.002","article-title":"Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: a review","volume":"177","author":"Blakely","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lanepe.2024.100840_bib68","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/cancers12082313","article-title":"Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe","volume":"12","author":"Uyl-de Groot","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.lanepe.2024.100840_bib69","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1200\/JCO.2010.34.1248","article-title":"Evaluation of oncology drugs at the European medicines agency and US Food and drug administration: when differences have an impact on clinical practice","volume":"29","author":"Trotta","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100840_bib70","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1468-0009.12476","article-title":"Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States","volume":"98","author":"Salcher-Konrad","year":"2020","journal-title":"Milbank Q"},{"issue":"10","key":"10.1016\/j.lanepe.2024.100840_bib74","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.7326\/M23-0623","article-title":"Regulatory review duration and differences in submission times of drugs in the United States and Europe, 2011 to 2020","volume":"176","author":"Vokinger","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lanepe.2024.100840_bib76","author":"Medicines And Healthcare Products Regulatory Agency"},{"issue":"24","key":"10.1016\/j.lanepe.2024.100840_bib77","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1158\/1078-0432.CCR-20-3292","article-title":"Project Orbis: global collaborative review program","volume":"26","author":"de Claro","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100840_bib79","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/S1470-2045(22)00701-X","article-title":"From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit","volume":"24","author":"Lythgoe","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2024.100840_bib81","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/EDBK_100028","article-title":"An arm and a leg: the rising cost of cancer drugs and impact on access","volume":"41","author":"Leighl","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.lanepe.2024.100840_bib83","author":"IQVIA"},{"key":"10.1016\/j.lanepe.2024.100840_bib85","author":"Gemeinsamer Bundesausschuss"},{"issue":"4","key":"10.1016\/j.lanepe.2024.100840_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101593","article-title":"Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit","volume":"8","author":"Hofmarcher","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.lanepe.2024.100840_bib89","series-title":"Vereniging Innovatieve Geneesmiddelen: Medicijnen voor de Samenleving","year":"2022"},{"issue":"1","key":"10.1016\/j.lanepe.2024.100840_bib90","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/1759-7714.13616","article-title":"Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: a whole-disease model","volume":"12","author":"Buja","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.lanepe.2024.100840_bib91","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12913-015-0725-3","article-title":"Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain)","volume":"15","author":"Corral","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.lanepe.2024.100840_bib92","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/ejcts\/ezaa421","article-title":"Unplanned readmission and survival after video-assisted thoracic surgery and open thoracotomy in patients with non-small-cell lung cancer: a 12-month nationwide cohort study","volume":"59","author":"Bouabdallah","year":"2021","journal-title":"Eur J Cardio Thorac Surg"},{"key":"10.1016\/j.lanepe.2024.100840_bib93","doi-asserted-by":"crossref","first-page":"100841","DOI":"10.1016\/j.lanepe.2024.100841","article-title":"Challenges and controversies in resectable non-small cell lung cancer: a clinician\u2019s perspective","volume":"38","author":"Houda","year":"2024","journal-title":"Lancet Reg Health Eur"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T06:38:56Z","timestamp":1716014336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776224000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":65,"alternative-id":["S2666776224000061"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100840","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100841","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100873","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100838","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100839","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100840"}}